Prolight Diagnostics publishes investorletter for March 2026

Nyheter Prolight Diagnostics Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Prolight Diagnostics publishes investorletter for March 2026

The investor letter highlights that Prolight has entered the year with several important milestones that further strengthen the position of our POC platform, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury (TBI).

Read more about this exciting development in the attached document or on the company’s website:
https://prolightdx.com/en/mediaeng/investor-letters/

About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Datum	2026-03-24, kl 08:15
Källa	MFN

Bifogade filer

	Prolight Diagnostics - Investorletter March 2026
	Prolight Diagnostics publishes investorletter for March 2026

LOGGA IN

Prolight Diagnostics

Affiliate

Prolight Diagnostics publishes investorletter for March 2026